PMID- 25500683
OWN - NLM
STAT- MEDLINE
DCOM- 20150916
LR  - 20181202
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 11
IP  - 4
DP  - 2015 Apr
TI  - Ultrasound contrast-enhanced imaging and in vitro antitumor effect of 
      paclitaxel-poly(lactic-co-glycolic acid)-monomethoxypoly (ethylene glycol) 
      nanocapsules with ultrasound-targeted microbubble destruction.
PG  - 2413-20
LID - 10.3892/mmr.2014.3072 [doi]
AB  - A combination of diagnostic and therapeutic ultrasound (US) techniques may be 
      able to provide the basis of specific therapeutic protocols, particularly for the 
      treatment of tumors. Nanotechnology may aid the progression towards the use of US 
      for tumor diagnosis and targeted therapy. The current study investigated in vivo 
      and in vitro US contrast imaging using nanocapsules (NCs), and also US and 
      US‑targeted microbubble destruction (UTMD) therapy using drug‑loaded NCs for 
      pancreatic cancer in vitro. In the current study, the NCs were made from the 
      polymer nanomaterial poly(lactic‑co‑glycolic acid)‑monomethoxypoly(ethylene 
      glycol) (PLGA‑mPEG), encapsulated with paclitaxel (PTX), to create PTX‑PLGA‑mPEG 
      NCs. The PTX‑PLGA‑mPEG NCs were used as a US contrast agent (UCA), which produced 
      satisfactory US contrast‑enhanced images in vitro and in vivo of the rabbit 
      kidneys, with good contrast compared with lesions in the peripheral regions. 
      However, clear contrast‑enhanced images were not obtained using PTX‑PLGA‑mPEG NCs 
      as a UCA, when imaging the superficial pancreatic tumors of nude mice in vivo. 
      Subsequently, fluorescence and flow cytometry were used to measure the NC uptake 
      rate of pancreatic tumor cells under various US or UTMD conditions. An MTT assay 
      was used to evaluate the efficiency of PTX and PTX‑PLGA‑mPEG NCs in killing tumor 
      cells following 24 or 48 h of US or UTMD therapy, compared with controls. The 
      specific US or UTMD conditions had been previously demonstrated to be optimal 
      through repeated testing, to determine the conditions by which cells were not 
      impaired and the efficiency of uptake of nanoparticles was highest. The current 
      study demonstrated high cellular uptake rates of PLGA‑mPEG NCs and high tumor 
      cell mortality with PTX‑PLGA‑mPEG NCs under US or UTMD optimal conditions. It was 
      concluded that the use of NCs in US‑mediated imaging and antitumor therapy may 
      provide a novel application for US.
FAU - Ma, Jing
AU  - Ma J
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Xing, Ling Xi
AU  - Xing LX
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Shen, Ming
AU  - Shen M
AD  - Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao tong University 
      School of Medicine, Shanghai 200032, P.R. China.
FAU - Li, Fan
AU  - Li F
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Zhu, Ming Jie
AU  - Zhu MJ
AD  - Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao tong University 
      School of Medicine, Shanghai 200032, P.R. China.
FAU - Jin, Li Fang
AU  - Jin LF
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Li, Zhaojun
AU  - Li Z
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Gao, Feng
AU  - Gao F
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Su, Yijin
AU  - Su Y
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
FAU - Duan, You Rong
AU  - Duan YR
AD  - Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao tong University 
      School of Medicine, Shanghai 200032, P.R. China.
FAU - Du, Lian Fang
AU  - Du LF
AD  - Department of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai 
      Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141210
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Contrast Media)
RN  - 0 (Drug Carriers)
RN  - 0 (Nanocapsules)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage
MH  - Cell Line, Tumor
MH  - *Contrast Media
MH  - Drug Carriers/chemistry
MH  - Drug Delivery Systems
MH  - Flow Cytometry
MH  - Humans
MH  - *Lactic Acid/chemistry
MH  - Mice
MH  - *Microbubbles
MH  - Microscopy, Fluorescence
MH  - *Nanocapsules/chemistry/ultrastructure
MH  - Neoplasms/*diagnostic imaging/*drug therapy
MH  - Paclitaxel/*administration & dosage
MH  - Particle Size
MH  - *Polyglycolic Acid/chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Ultrasonography/*methods
PMC - PMC4337512
EDAT- 2014/12/17 06:00
MHDA- 2015/09/17 06:00
PMCR- 2014/12/10
CRDT- 2014/12/16 06:00
PHST- 2014/01/10 00:00 [received]
PHST- 2014/10/02 00:00 [accepted]
PHST- 2014/12/16 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/09/17 06:00 [medline]
PHST- 2014/12/10 00:00 [pmc-release]
AID - mmr-11-04-2413 [pii]
AID - 10.3892/mmr.2014.3072 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Apr;11(4):2413-20. doi: 10.3892/mmr.2014.3072. Epub 2014 Dec 
      10.